Ya-Wei Yuan1, Rong-Hui Zheng2, Hao-Yun Tao3, Hui Liu3, Fang He4, Cai-Xian He3, Ran Li5, Kun-Peng Du3. 1. Department of Radiation Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, Guangdong, China. yuanyawei@gzhmu.edu.cn. 2. Department of Radiation Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, Guangdong, China. zhengronghui@gzhmu.edu.cn. 3. Department of Radiation Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, Guangdong, China. 4. Department of Radiation Oncology, People's Hospital of Zhongshan City, Zhongshan, Guangdong, China. 5. Department of Pediatrics, Longhua District People's Hospital, Shenzhen, Guangdong, China.
Abstract
OBJECTIVE: This study aimed to explore the clinical value of adjuvant chemotherapy (ACT) following concurrent chemo-radiotherapy (CCRT) and induction chemotherapy (ICT) in loco-regionally advanced nasopharyngeal carcinoma (LANC). METHODS: We included 839 newly diagnosed LANC patients in this study. ICT plus CCRT (ICT + CCRT group) was administered to 443 patients, and 396 patients received ACT after ICT plus CCRT (ICT + CCRT + ACT group). Univariate and multivariate Cox regression analyses were carried out. Furthermore, propensity score matching (PSM) was applied to balance the study and control groups. RESULTS: A total of 373 pairs of LANC patients were obtained after PSM analysis. We found that ACT following ICT + CCRT has no significant effect on improving the survival of LANC patients. By further exploring the ICT + CCRT + ACT treatment protocol, we excluded N0-1-positive patients and re-performed PSM in the ICT + CCRT and ICT + CCRT + ACT groups. Each group consisted of 237 patients. Kaplan-Meier analysis revealed that there were differences between the ICT + CCRT and ICT + CCRT + ACT groups in terms of the 5-year overall survival (OS) (78.9% vs. 85.0%, P = 0.034), disease-free survival (DFS) (73.4% vs. 81.7%, P = 0.029), and distant metastasis-free survival (DMFS) (84.9% vs. 76.0%, P = 0.019). In addition, the ICT + CCRT + ACT group had a higher incidence of grade 3/4 acute leukocytopenia/neutropenia. CONCLUSION: Compared with ICT + CCRT, ACT following ICT plus CCRT can reduce distant metastasis of N2-3-positive LANC and improve the OS and DFS. The results demonstrated the feasibility and clinical utility of ACT following ICT plus CCRT.
OBJECTIVE: This study aimed to explore the clinical value of adjuvant chemotherapy (ACT) following concurrent chemo-radiotherapy (CCRT) and induction chemotherapy (ICT) in loco-regionally advanced nasopharyngeal carcinoma (LANC). METHODS: We included 839 newly diagnosed LANC patients in this study. ICT plus CCRT (ICT + CCRT group) was administered to 443 patients, and 396 patients received ACT after ICT plus CCRT (ICT + CCRT + ACT group). Univariate and multivariate Cox regression analyses were carried out. Furthermore, propensity score matching (PSM) was applied to balance the study and control groups. RESULTS: A total of 373 pairs of LANC patients were obtained after PSM analysis. We found that ACT following ICT + CCRT has no significant effect on improving the survival of LANC patients. By further exploring the ICT + CCRT + ACT treatment protocol, we excluded N0-1-positive patients and re-performed PSM in the ICT + CCRT and ICT + CCRT + ACT groups. Each group consisted of 237 patients. Kaplan-Meier analysis revealed that there were differences between the ICT + CCRT and ICT + CCRT + ACT groups in terms of the 5-year overall survival (OS) (78.9% vs. 85.0%, P = 0.034), disease-free survival (DFS) (73.4% vs. 81.7%, P = 0.029), and distant metastasis-free survival (DMFS) (84.9% vs. 76.0%, P = 0.019). In addition, the ICT + CCRT + ACT group had a higher incidence of grade 3/4 acute leukocytopenia/neutropenia. CONCLUSION: Compared with ICT + CCRT, ACT following ICT plus CCRT can reduce distant metastasis of N2-3-positive LANC and improve the OS and DFS. The results demonstrated the feasibility and clinical utility of ACT following ICT plus CCRT.
Authors: Anthony T C Chan; S F Leung; Roger K C Ngan; Peter M L Teo; W H Lau; W H Kwan; Edwin P Hui; H Y Yiu; Winnie Yeo; F Y Cheung; K H Yu; K W Chiu; D T Chan; Tony S K Mok; Stephen Yau; K T Yuen; Frankie K F Mo; Maria M P Lai; Brigette B Y Ma; Michael K M Kam; Thomas W T Leung; Philip J Johnson; Peter H K Choi; Benny C Y Zee Journal: J Natl Cancer Inst Date: 2005-04-06 Impact factor: 13.506
Authors: M Al-Sarraf; M LeBlanc; P G Giri; K K Fu; J Cooper; T Vuong; A A Forastiere; G Adams; W A Sakr; D E Schuller; J F Ensley Journal: J Clin Oncol Date: 1998-04 Impact factor: 44.544
Authors: Yu-Pei Chen; Nofisat Ismaila; Melvin L K Chua; A Dimitrios Colevas; Robert Haddad; Shao Hui Huang; Joseph T S Wee; Alexander C Whitley; Jun-Lin Yi; Sue S Yom; Anthony T C Chan; Chao-Su Hu; Jin-Yi Lang; Quynh-Thu Le; Anne W M Lee; Nancy Lee; Jin-Ching Lin; Brigette Ma; Thomas J Morgan; Jatin Shah; Ying Sun; Jun Ma Journal: J Clin Oncol Date: 2021-01-06 Impact factor: 44.544